Efficacy and safety of luseogliflozin in Caucasian patients with type 2 diabetes: results from a phase III, randomized, placebo-controlled, clinical trial.

Comparisons between the luseo groups and PCB, expressed as LS means, revealed significant reductions in FPG of −0.63 and −0.66 mmol/L in the luseo 5 and 10 mg groups (p=0.022 for both groups); the −0.38 mmol/L reduction in the 2.5 mg group did not reach statistical significance (p=0.131).

also in 111,027 other papers